For Exer-Rest acceleration therapeutic platform
The Canadian Patent Office has issued Patent number 2534302 to Non-Invasive Monitoring Systems (NIMS) on October 20, 2009. The patent, entitled ‘Reciprocating Movement Platform for the External Addition of Pulses to the Fluid Channels of a Subject’, relates to the comprehensively researched technology underlying NIMS’ Exer-Rest acceleration therapeutic platform.
Reportedly, the Canadian patent that expires August 4, 2024, incorporates 55 claims dealing with treatment of acute and chronic inflammatory diseases and is the Canadian counterpart to US Patent No 7404221, the fifth patent issued for this technology.
NIMS is authorised to sell the Exer-Rest in Canada as a class II medical device with CE certification. The Exer-Rest is intended as an aid to improve circulation, increase joint mobility, and to provide temporary relief of minor aches and pains.
The Exer-Rest is currently being marketed and sold in the US, Canada and other major international markets. It has been cleared by FDA as an aid to temporarily increase local circulation, to provide temporary relief of minor aches and pains, to reduce morning stiffness and to provide local muscle relaxation. The Exer-Rest is also approved for sale in Europe as an aid to increase mobility.
Marvin Sackner, founder and CEO of NIMS, said: “This Canadian patent builds on the company’s global intellectual property and provides protection in our efforts to market in Canada.”